Visus Therapeutics raises $36M Series A from Johnson & Johnson Innovation, RTW Investments and others to advance BRIMOCHOL presbyopia eye drop
Visus Therapeutics, a Seattle startup developing BRIMOCHOL, a once-daily presbyopia-correcting eye drop, raised $36 million in a Series A led in part by Johnson & Johnson Innovation alongside RTW Investments, Wille AG and existing investors.
No comments yet.